AR119943A1 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- AR119943A1 AR119943A1 ARP200102527A ARP200102527A AR119943A1 AR 119943 A1 AR119943 A1 AR 119943A1 AR P200102527 A ARP200102527 A AR P200102527A AR P200102527 A ARP200102527 A AR P200102527A AR 119943 A1 AR119943 A1 AR 119943A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- alkoxy
- compounds
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente proporciona compuestos heterocíclicos que tienen la fórmula general (1) en donde A, B, L¹, X, m, n, y R¹ a R⁷ son como se describen en la presente, composiciones que incluyen los compuestos, procesos de elaboración de los compuestos y métodos de uso de los compuestos. Reivindicación 1: Un compuesto de la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A se selecciona de C₆₋₁₄-arilo, heteroarilo de 5 a 14 miembros y heterociclilo de 3 a 14 miembros; B es (i) C₆₋₁₄-arilo; y L¹ es -O-; o (ii) heteroarilo de 5 a 14 miembros; y L¹ es un enlace covalente u -O-; m es 0, n es 0 ó 1 y X es CR⁸; o m es 1, n es 1 ó 2 y X es CR⁸ o N; R¹, R² y R³ se seleccionan independientemente de hidrógeno y C₁₋₆-alquilo; R⁴, R⁵, R⁶ y R⁷ se seleccionan independientemente de hidrógeno, halógeno, ciano, hidroxi, C₁₋₆-alcoxi, halo-C₁₋₆-alcoxi, amino-C₁₋₆-alcoxi, C₁₋₆-alquilo, halo-C₁₋₆-alquilo, hidroxi-C₁₋₆-alquilo, C₁₋₆-alquilsulfonilo, SF₅, carbamoilo, C₃₋₁₀-cicloalquil-C₁₋₆-alcoxi-, C₁₋₆-alquil-NH-C(O)-, C₁₋₆-alquil-C(O)-NH- y C₃₋₁₀-cicloalquilo, en donde cada uno de C₃₋₁₀-cicloalquilo está opcionalmente sustituido con 1 - 2 sustituyentes seleccionados de C₁₋₆-alquilo y halo-C₁₋₆-alquilo; y R⁸ se selecciona de hidrógeno, halógeno, hidroxi, halo-C₁₋₆-alquilo y C₁₋₆-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196879 | 2019-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119943A1 true AR119943A1 (es) | 2022-01-19 |
Family
ID=67953598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102527A AR119943A1 (es) | 2019-09-12 | 2020-09-11 | Compuestos heterocíclicos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11814375B2 (es) |
| EP (1) | EP4028403B1 (es) |
| JP (1) | JP2022548028A (es) |
| KR (1) | KR20220062515A (es) |
| CN (1) | CN114269755A (es) |
| AR (1) | AR119943A1 (es) |
| AU (1) | AU2020346350A1 (es) |
| BR (1) | BR112022002375A2 (es) |
| CA (1) | CA3151516A1 (es) |
| CL (1) | CL2022000556A1 (es) |
| CO (1) | CO2022001879A2 (es) |
| CR (1) | CR20220104A (es) |
| IL (1) | IL289186A (es) |
| MX (1) | MX2022002311A (es) |
| PE (1) | PE20220565A1 (es) |
| TW (1) | TW202128706A (es) |
| WO (1) | WO2021048242A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| JP2021534139A (ja) | 2018-08-13 | 2021-12-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物 |
| BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
| JP2023508907A (ja) | 2019-12-20 | 2023-03-06 | テナヤ セラピューティクス， インコーポレイテッド | フルオロアルキル－オキサジアゾールおよびその使用 |
| EP4208456A1 (en) | 2020-09-03 | 2023-07-12 | F. Hoffmann-La Roche AG | Heterocyclic compounds |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214038A (en) | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| CA2609957A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| EP1984351A1 (en) | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| TW200938542A (en) | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2010049302A1 (en) | 2008-10-29 | 2010-05-06 | F. Hoffmann-La Roche Ag | Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| AU2012255690B2 (en) | 2011-05-16 | 2015-06-11 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| WO2013059118A1 (en) | 2011-10-19 | 2013-04-25 | The Trustees Of Columbia University In The City Of New York | Cyclopropenimine catalyst compositions and processes |
| CN103958525A (zh) | 2011-11-30 | 2014-07-30 | 埃科特莱茵药品有限公司 | 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素 |
| SG11201402237WA (en) | 2011-12-22 | 2014-09-26 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| BR112014016672B1 (pt) | 2012-01-06 | 2022-06-28 | The Scripps Research Institute | Compostos de carbamato, composição farmaceutica e uso dos referidos compostos |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| KR20150143720A (ko) | 2013-04-16 | 2015-12-23 | 액테리온 파마슈티칼 리미티드 | 항균성 이방향족 유도체 |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| JP6653319B2 (ja) * | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3294729A1 (en) | 2015-05-13 | 2018-03-21 | Selvita S.A. | Substituted quinoxaline derivatives |
| JP6703553B2 (ja) | 2015-05-21 | 2020-06-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｐａｄ４阻害剤としてのベンゾイミダゾール誘導体 |
| CA3014432C (en) | 2015-06-18 | 2024-05-07 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10323026B2 (en) | 2016-03-31 | 2019-06-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3438109B1 (en) | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA039223B1 (ru) | 2017-06-12 | 2021-12-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероароматические соединения в качестве ингибиторов ванина |
| KR102668900B1 (ko) | 2017-09-29 | 2024-05-24 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환형 화합물 |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3717477B1 (en) * | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| SG11202007608UA (en) * | 2018-03-22 | 2020-09-29 | Hoffmann La Roche | Oxazine monoacylglycerol lipase (magl) inhibitors |
| JP2021534139A (ja) * | 2018-08-13 | 2021-12-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物 |
| MX2020013719A (es) | 2018-08-13 | 2021-03-02 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa. |
| CU20210042A7 (es) | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| CA3119506A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| EP3953360B1 (en) | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| PE20220514A1 (es) | 2019-07-03 | 2022-04-07 | Hoffmann La Roche | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos |
| PE20220515A1 (es) | 2019-07-09 | 2022-04-07 | Hoffmann La Roche | Nuevos compuestos heterociclicos |
| US20210094971A1 (en) | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| WO2021048241A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
| BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
| PE20221450A1 (es) | 2019-09-23 | 2022-09-21 | Hoffmann La Roche | Compuestos heterociclicos |
| MX2022002711A (es) | 2019-09-24 | 2022-03-22 | Hoffmann La Roche | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). |
| US20210094972A1 (en) * | 2019-09-24 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| JP2022549306A (ja) | 2019-09-24 | 2022-11-24 | エフ．ホフマン－ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ（ｍａｇｌ）の蛍光プローブ |
| EP4208456A1 (en) | 2020-09-03 | 2023-07-12 | F. Hoffmann-La Roche AG | Heterocyclic compounds |
-
2020
- 2020-09-10 BR BR112022002375A patent/BR112022002375A2/pt unknown
- 2020-09-10 CR CR20220104A patent/CR20220104A/es unknown
- 2020-09-10 WO PCT/EP2020/075260 patent/WO2021048242A1/en active Application Filing
- 2020-09-10 PE PE2022000245A patent/PE20220565A1/es unknown
- 2020-09-10 MX MX2022002311A patent/MX2022002311A/es unknown
- 2020-09-10 KR KR1020227007925A patent/KR20220062515A/ko unknown
- 2020-09-10 JP JP2022516054A patent/JP2022548028A/ja active Pending
- 2020-09-10 US US17/017,200 patent/US11814375B2/en active Active
- 2020-09-10 CN CN202080059190.8A patent/CN114269755A/zh active Pending
- 2020-09-10 AU AU2020346350A patent/AU2020346350A1/en not_active Abandoned
- 2020-09-10 CA CA3151516A patent/CA3151516A1/en active Pending
- 2020-09-10 EP EP20774901.1A patent/EP4028403B1/en active Active
- 2020-09-11 TW TW109131236A patent/TW202128706A/zh unknown
- 2020-09-11 AR ARP200102527A patent/AR119943A1/es unknown
-
2021
- 2021-12-20 IL IL289186A patent/IL289186A/en unknown
-
2022
- 2022-02-22 CO CONC2022/0001879A patent/CO2022001879A2/es unknown
- 2022-03-07 CL CL2022000556A patent/CL2022000556A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4028403B1 (en) | 2023-11-22 |
| TW202128706A (zh) | 2021-08-01 |
| EP4028403C0 (en) | 2023-11-22 |
| BR112022002375A2 (pt) | 2022-07-19 |
| WO2021048242A1 (en) | 2021-03-18 |
| CR20220104A (es) | 2022-04-20 |
| JP2022548028A (ja) | 2022-11-16 |
| CO2022001879A2 (es) | 2022-03-29 |
| PE20220565A1 (es) | 2022-04-13 |
| CA3151516A1 (en) | 2021-03-18 |
| KR20220062515A (ko) | 2022-05-17 |
| MX2022002311A (es) | 2022-03-25 |
| IL289186A (en) | 2022-02-01 |
| CL2022000556A1 (es) | 2022-10-21 |
| US20210094943A1 (en) | 2021-04-01 |
| AU2020346350A1 (en) | 2022-02-17 |
| EP4028403A1 (en) | 2022-07-20 |
| CN114269755A (zh) | 2022-04-01 |
| US11814375B2 (en) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119943A1 (es) | Compuestos heterocíclicos | |
| AR110405A1 (es) | Compuestos | |
| AR120030A1 (es) | Compuestos heterocíclicos | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR111279A1 (es) | Derivados heterocíclicos útiles como inhibidores duales de atx / ca | |
| AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR120697A1 (es) | Inhibidores de braf como rompedores de la paradoja | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR121985A1 (es) | Compuestos de azalactama como inhibidores de hpk1 | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| AR119790A1 (es) | Compuestos de isoxazolina y su uso como agentes para el control de plagas | |
| AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor | |
| AR122726A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR122517A1 (es) | Isoxazolidinas como inhibidores de ripk1 y usos de las mismas | |
| AR125907A1 (es) | Nueva piridina sustituida | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR125365A1 (es) | Derivados de 1h-pirazol como ligandos sigma | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| AR121344A1 (es) | Compuestos heterocíclicos fusionados y su uso como agentes para el control de plagas |